Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cereno Scientific ABFRA:4A1 +4.69%39 Days Payable is 0.00 as of Mar. 2026. GuruFocus rates FRA:4A1 with a GF Score™ of 39/100. The stock has 3 warning signs investors should review. Among 927 Drug Manufacturers companies, Cereno Scientific AB ranks worse than 107874.76% on this metric.
The historical rank and industry rank for Cereno Scientific AB's Days Payable or its related term are showing as below:
FRA:4A1's Days Payable is not ranked *
in the Drug Manufacturers industry.
Industry Median: 90.28 * Ranked among companies with meaningful Days Payable only.
Cereno Scientific AB's Days Payable
stayed the same
from Mar. 2025 (0.00) to Mar. 2026 (0.00).
stayed the same
The historical data trend for Cereno Scientific AB's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cereno Scientific AB's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cereno Scientific AB Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cereno Scientific AB's Days Payable distribution charts can be found below:
* The bar in red indicates where Cereno Scientific AB's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Cereno Scientific AB's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cereno Scientific AB (FRA:4A1) has a Days Payable of 0.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Cereno Scientific AB and its competitors. According to the industry distribution chart, Cereno Scientific AB ranks #999999 out of 927 companies in the Drug Manufacturers industry.
Is Cereno Scientific AB's Days Payable too high?
Cereno Scientific AB's current Days Payable is 0.00. Based on the distribution chart, Cereno Scientific AB ranks #999999 out of 927 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Cereno Scientific AB has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Cereno Scientific AB's Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cereno Scientific AB ranks #999999 out of 927 companies for Days Payable. This places Cereno Scientific AB in the lower half of its industry. The industry median Days Payable is 90.28. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.28, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Cereno Scientific AB and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cereno Scientific AB's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cereno Scientific AB stock overvalued right now?
Cereno Scientific AB (FRA:4A1) has a current Days Payable of 0.00. The current Days Payable is 0.00. Cereno Scientific AB's overall GF Score™ is 39/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Cereno Scientific AB (FRA:4A1), the current Days Payable is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cereno Scientific AB is developing a pipeline of preventive therapeutics to treat cardiovascular and rare diseases by epigenetic modulation through histone deacetylase inhibition (HDACi). The company's program, CS1, is a phase two dual-acting antithrombotic drug aimed at venous thrombosis and stroke prevention for atrial fibrillation. It also evaluates the potential of epigenetic modulation for rare diseases related to pulmonary fibrosis, thrombosis, inflammation, and high blood pressure in the pulmonary circulation system.
39GF Score
Get the complete analysis for FRA:4A1
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4A1 has been successfully added to your 
